MX2015015036A - Metodos para mejorar los perfiles de lipidos utilizando atrasentan. - Google Patents
Metodos para mejorar los perfiles de lipidos utilizando atrasentan.Info
- Publication number
- MX2015015036A MX2015015036A MX2015015036A MX2015015036A MX2015015036A MX 2015015036 A MX2015015036 A MX 2015015036A MX 2015015036 A MX2015015036 A MX 2015015036A MX 2015015036 A MX2015015036 A MX 2015015036A MX 2015015036 A MX2015015036 A MX 2015015036A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- atrasentan
- cholesterol
- subject
- lipid profiles
- Prior art date
Links
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 title abstract 2
- 229950010993 atrasentan Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 150000002632 lipids Chemical class 0.000 title 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361817645P | 2013-04-30 | 2013-04-30 | |
| US201361824199P | 2013-05-16 | 2013-05-16 | |
| PCT/US2014/036152 WO2014179453A1 (en) | 2013-04-30 | 2014-04-30 | Methods for improving lipid profiles using atrasentan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015015036A true MX2015015036A (es) | 2016-02-09 |
Family
ID=50928265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015036A MX2015015036A (es) | 2013-04-30 | 2014-04-30 | Metodos para mejorar los perfiles de lipidos utilizando atrasentan. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9855245B2 (enExample) |
| EP (1) | EP2991680A1 (enExample) |
| JP (1) | JP2016521279A (enExample) |
| KR (1) | KR20160003128A (enExample) |
| CN (1) | CN105246512A (enExample) |
| AU (1) | AU2014259961A1 (enExample) |
| BR (1) | BR112015027631A2 (enExample) |
| CA (1) | CA2909871A1 (enExample) |
| HK (1) | HK1221916A1 (enExample) |
| MX (1) | MX2015015036A (enExample) |
| RU (1) | RU2015151175A (enExample) |
| SG (1) | SG11201508960SA (enExample) |
| WO (1) | WO2014179453A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101890959B1 (ko) | 2010-11-04 | 2018-08-22 | 알비레오 에이비 | 간질환 치료를 위한 ｉｂａｔ 억제제 |
| CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| CN116327758A (zh) | 2019-12-17 | 2023-06-27 | 奇努克医疗公司 | 用阿曲生坦治疗IgA肾病的方法 |
| WO2021207723A2 (en) * | 2020-04-10 | 2021-10-14 | Chinook Therapeutics, Inc. | Methods of treating diabetic kidney disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2799241A (en) | 1949-01-21 | 1957-07-16 | Wisconsin Alumni Res Found | Means for applying coatings to tablets or the like |
| US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
| NL271831A (enExample) | 1960-11-29 | |||
| US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
| US3546142A (en) | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
| US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
| US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US5286497A (en) | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
| US5573776A (en) | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| US5544163A (en) | 1994-03-08 | 1996-08-06 | Excel, Inc. | Expandable telecommunications system |
| US5767144A (en) | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
| US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| US7365093B2 (en) | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| US7208517B1 (en) | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| CL2004000545A1 (es) * | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul |
| WO2006034094A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 1 of atrasentan hxdrochloride |
| WO2006034084A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 2 of atrasentan hydrochloride |
| WO2006034234A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 3 of atrasentan hydrochloride |
| US20060135596A1 (en) | 2004-09-17 | 2006-06-22 | Zhang Geoff G | Amorphous form of a drug |
| US20070004745A1 (en) * | 2005-03-25 | 2007-01-04 | Schering-Plough Corporation | Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors |
| US20080132710A1 (en) | 2006-12-04 | 2008-06-05 | Abbott Laboratories | Atrasentan hydrochloride crystalline form 2 |
| CA2904447C (en) | 2007-08-22 | 2017-01-03 | Abbvie Deutschland Gmbh & Co Kg | Therapy for complications of diabetes |
| CN101822837A (zh) * | 2010-02-02 | 2010-09-08 | 王丽燕 | 包含艾力沙坦酯盐的药物组合物 |
| CA2901922A1 (en) | 2013-03-08 | 2014-09-12 | Abbvie Inc. | Methods of treating acute kidney injury |
-
2014
- 2014-04-30 JP JP2016512012A patent/JP2016521279A/ja active Pending
- 2014-04-30 KR KR1020157033693A patent/KR20160003128A/ko not_active Withdrawn
- 2014-04-30 EP EP14729532.3A patent/EP2991680A1/en not_active Withdrawn
- 2014-04-30 US US14/888,195 patent/US9855245B2/en not_active Expired - Fee Related
- 2014-04-30 SG SG11201508960SA patent/SG11201508960SA/en unknown
- 2014-04-30 MX MX2015015036A patent/MX2015015036A/es unknown
- 2014-04-30 CN CN201480032387.7A patent/CN105246512A/zh active Pending
- 2014-04-30 AU AU2014259961A patent/AU2014259961A1/en not_active Abandoned
- 2014-04-30 WO PCT/US2014/036152 patent/WO2014179453A1/en not_active Ceased
- 2014-04-30 RU RU2015151175A patent/RU2015151175A/ru not_active Application Discontinuation
- 2014-04-30 CA CA2909871A patent/CA2909871A1/en not_active Abandoned
- 2014-04-30 HK HK16110230.1A patent/HK1221916A1/zh unknown
- 2014-04-30 BR BR112015027631A patent/BR112015027631A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN105246512A (zh) | 2016-01-13 |
| US20160074363A1 (en) | 2016-03-17 |
| KR20160003128A (ko) | 2016-01-08 |
| CA2909871A1 (en) | 2014-11-06 |
| WO2014179453A1 (en) | 2014-11-06 |
| EP2991680A1 (en) | 2016-03-09 |
| BR112015027631A2 (pt) | 2017-08-22 |
| JP2016521279A (ja) | 2016-07-21 |
| US9855245B2 (en) | 2018-01-02 |
| AU2014259961A1 (en) | 2015-11-05 |
| RU2015151175A (ru) | 2017-06-07 |
| HK1221916A1 (zh) | 2017-06-16 |
| SG11201508960SA (en) | 2015-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015015036A (es) | Metodos para mejorar los perfiles de lipidos utilizando atrasentan. | |
| BR112014014262A2 (pt) | nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas. | |
| WO2014062720A3 (en) | Methods of treating cancer | |
| IN2015DN03219A (enExample) | ||
| SG195110A1 (en) | Pirfenidone and anti-fibrotic therapy in selected patients | |
| IN2014DN10386A (enExample) | ||
| AU2012229123A8 (en) | Methods of treating breast cancer with anthracycline therapy | |
| IN2014MN01892A (enExample) | ||
| NZ628433A (en) | Chitosan-derived compositions | |
| MX364220B (es) | Metodos de tratamientos de fibrosis. | |
| MX2019008817A (es) | Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma. | |
| MX362861B (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionadods. | |
| CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
| MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
| MX2015006370A (es) | Suplementos herbales y metodos para utilizar los mismos. | |
| NZ616048A (en) | Administration of iloprost as aerosol bolus | |
| MX2016000220A (es) | Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp. | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
| PH12016500142A1 (en) | Vesicles | |
| MX339834B (es) | Regimen terapeutico y metodos para tratar o mejorar trastornos visuales asociados a deficiencia endogena de retinoide. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| PH12014500327A1 (en) | Method of transforming a meal | |
| MX366309B (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| BR112014029308A2 (pt) | um método de melhorar a função hepática |